BridgeBio

We are hosting a satellite symposium onsite at this year’s European Society of Cardiology with top cardiologists in the space to discuss the important role of transthyretin in ATTR-CM. Learn more about the program: https://bit.ly/3yslD6p 

We are on a mission to discover, create, test, and deliver transformative medicines for patients with genetic conditions. Learn more about our upcoming presentations for September where we will discuss our upcoming milestones: https://bit.ly/3APGCAJ

We will present insights from ATTRibute-CM, our Phase 3 trial in patients with transthyretin amyloidosis, and its open-label extension at the European Society of Cardiology in a moderated poster session this year. Learn more: https://bit.ly/4dpzYzC

We’re thrilled to announce that BridgeBio is partnering with the Cardiovascular Data Science (CarDS) Lab, led by Dr. Rohan Khera at Yale School of Medicine, to address the underdiagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM). By leveraging multimodal artificial intelligence, our partnership will aim to enhance diagnostic accuracy and ensure more patients receive timely and effective care, which has long been an unmet need for patients. Learn more: https://bit.ly/3AJx4XX

In our latest episode of the #OnRarePodcast, we hear from Dawn, the mother of Vayle who is living with Canavan disease, which begins in infancy and progresses rapidly, affecting Vayle's ability to play or participate in any daily activities without her mother's hands-on support. Listen to Dawn describe the love and care she gives her daughter in this episode: https://bit.ly/3SLB8xf

The most beneficial TTR gene variant identified to date is T119M, which has shown to offer protection against the development of ATTR‑CM even when coinherited with variants associated with poor outcomes.

Tomorrow, Srivatsan Ramesh Ph.D., scientist I of downstream process development at BridgeBio Gene Therapy, will speak about reducing process development timelines with rapid, high-throughput orthogonal assays and a robust downstream process. Learn more about the event: https://bit.ly/4fqDcEo

We’re thrilled to share that we have officially launched MyAchonJourney, a new online resource to support individuals and families living with achondroplasia. This initiative will provide ongoing, evolving support tailored to families at every stage of their life with achondroplasia. We are grateful to the community leaders and skeletal dysplasia experts, who helped develop this asset with the intention of empowering individuals with achondroplasia to lead enriching lives. Learn more: https://bit.ly/3WHt160

Predictive biomarkers of ATTR‐CM can help lead to earlier intervention and allow physicians to better understand and develop a treatment plan for patients with this relentlessly progressive heart disease.

The progression of ATTR‑CM lessens people’s strength, mobility, and independence. While advancements have been made, there is still work to fulfill unmet needs for patients.